203 related articles for article (PubMed ID: 20142333)
1. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.
Perboni G; Costa P; Fibbia GC; Morandini B; Scalzini A; Tagliani A; Cengarle R; Aitini E
Oncologist; 2010; 15(2):142-5. PubMed ID: 20142333
[TBL] [Abstract][Full Text] [Related]
2. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
Chelis L; Ntinos N; Souftas V; Deftereos S; Xenidis N; Chamalidou E; Maltezos E; Kakolyris S
Med Oncol; 2011 Dec; 28 Suppl 1():S165-8. PubMed ID: 20809183
[TBL] [Abstract][Full Text] [Related]
3. Complete response for advanced liver cancer during sorafenib therapy: case report.
Sacco R; Bargellini I; Gianluigi G; Bertini M; Bozzi E; Altomare E; Battaglia V; Romano A; Bertoni M; Capria A; Bresci G; Bartolozzi C
BMC Gastroenterol; 2011 Jan; 11():4. PubMed ID: 21241463
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
Berretta M; Di Benedetto F; Dal Maso L; Cacopardo B; Nasti G; Facchini G; Bearz A; Spina M; Garlassi E; De Re V; Fiorica F; Lleshi A; Tirelli U
Anticancer Drugs; 2013 Feb; 24(2):212-8. PubMed ID: 23197082
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
7. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
8. Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib.
Nunes G; Fonseca C; Patita M; Aleixo MJ; Ramalho M; Fonseca J
Turk J Gastroenterol; 2020 Feb; 31(2):184-186. PubMed ID: 32141829
[No Abstract] [Full Text] [Related]
9. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Kim R; Menon N; Aucejo F
Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the treatment of advanced hepatocellular carcinoma.
Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
[TBL] [Abstract][Full Text] [Related]
11. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Cabrera R; Limaye AR; Horne P; Mills R; Soldevila-Pico C; Clark V; Morelli G; Firpi R; Nelson DR
Aliment Pharmacol Ther; 2013 Jan; 37(1):91-7. PubMed ID: 23094860
[TBL] [Abstract][Full Text] [Related]
12. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Shim JH; Park JW; Choi JI; Park BJ; Kim CM
J Cancer Res Clin Oncol; 2009 Apr; 135(4):617-25. PubMed ID: 18846384
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Sakata K; Matsugaki S; Kajiwara M; Fukuizumi K; Tajiri N; Matsukuma N; Sakai T; Ono N; Yano Y; Koga H; Kurogi J; Takata A; Sumie S; Satani M; Yamada S; Niizeki T; Aino H; Iwamoto H; Torimura T; Sata M
Oncology; 2013; 84(2):108-14. PubMed ID: 23147476
[TBL] [Abstract][Full Text] [Related]
15. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
[TBL] [Abstract][Full Text] [Related]
16. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
[TBL] [Abstract][Full Text] [Related]
17. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
Wang Y; Speeg KV; Washburn WK; Halff G
World J Gastroenterol; 2010 Nov; 16(43):5518-22. PubMed ID: 21086573
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
20. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
Hsieh CH; Jeng KS; Lin CC; Chen CK; Liu CY; Lin CP; Tai HC; Wang CH; Shueng PW; Chen YJ
Clin Drug Investig; 2009; 29(1):65-71. PubMed ID: 19067476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
